📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Periodic Benefit-Risk Evaluation Report (OBX-319)
Why it exists. A pharmacovigilance document interpreting the safety data on the schedule regulators expect.
How it is produced here. It is a pharmacovigilance ('drug safety watch') document: it gathers and interprets the simulated safety data on the fixed schedule regulators expect once a drug enters development or the market.
Format & governing standard. —
Document ID: PSUR-001
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): ICH E2C(R2)
Periodic benefit-risk evaluation for OBX-319: worldwide exposure, signal and risk evaluation, and an integrated benefit-risk conclusion for the reporting interval. ICH E2C(R2).
Active substance (INN/proposed): OBX-319
Pharmacological class: Humanized IgG1 anti-CD19 × anti-CD20 B-cell-depleting bispecific monoclonal antibody
Modality / expression system: Recombinant bispecific IgG1; Chinese Hamster Ovary (CHO) cell culture
Route / presentation: Subcutaneous injection
Proposed indication: Moderate-to-severe active Systemic Lupus Erythematosus (SLE), on background standard-of-care
Virtual Biopharma Inc.
15 March 2022 (first administration in humans)
Not yet assigned — no marketing authorization granted in any country at the data lock point
31 December 2025
DIBD (15 March 2022) through DLP (31 December 2025); this is the inaugural report and figures are cumulative
Development Core Safety Information (DCSI) in the current Investigator's Brochure edition
ICH E2C(R2) Periodic Benefit-Risk Evaluation Report
No comments yet. Be the first to say something!
OBX-319 is a humanized immunoglobulin G1 (IgG1) bispecific monoclonal antibody engineered to bind two independent B-lineage surface antigens, CD19 and CD20, thereby producing deep, near-complete depletion of circulating and tissue-resident autoreactive B cells across a broader maturation window than agents directed at a single antigen. The dual-targeting design engages CD19 (expressed from the pro-B through plasmablast stages) and CD20 (expressed from the pre-B through memory B-cell stages), and is intended to overcome the antigen-escape and incomplete-depletion limitations observed with single-target B-cell-directed therapies. The molecule is a full-length IgG1 with a functional, effector-competent Fc, and depletion is mediated by antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), supplemented by direct pro-apoptotic signalling. OBX-319 is produced by recombinant CHO cell culture and purified by a platform downstream process anchored on Protein A affinity capture followed by orthogonal polishing chromatography; it is formulated for subcutaneous administration.
This document is the first Periodic Benefit-Risk Evaluation Report (PBRER) for OBX-319, prepared in the ICH E2C(R2) format to consolidate the worldwide benefit-risk assessment for the proposed indication of moderate-to-severe active SLE and to establish the periodic benefit-risk reporting cadence. The report is aligned in content and data lock with the corresponding Development Safety Update Report (ICH E2F) for the interval. At the DLP, OBX-319 is not marketed in any country; the Biologics License Application (BLA) is under review by the United States Food and Drug Administration (FDA) under 21 CFR Part 601, and additional regulatory submissions are in preparation. Accordingly, all cumulative exposure derives from the clinical development programme, and the benefit-risk evaluation is grounded principally in the completed pivotal Phase 3 study OBX319-301, supported by earlier-phase clinical data and the nonclinical programme conducted under ICH S6(R1).
The benefit-risk conclusion presented in Section 18 integrates the demonstrated clinical benefit in moderate-to-severe active SLE against the characterised and potential risks of profound B-cell depletion — principally serious and opportunistic infections and hypogammaglobulinaemia — together with the injection-reaction and immunogenicity profile expected of a subcutaneously administered therapeutic antibody.
OBX-319 holds no marketing authorization in any country or region at the DLP. There have been no approvals, no approvals subject to conditions, no refusals, no withdrawals of an application by the sponsor for safety or efficacy reasons, and no non-renewals during the reporting interval.
Regulatory status of the development programme at the DLP:
No indication, formulation, dosing, population, or manufacturing authorization exists to be summarised in the tabular authorization overview; the "proposed indication" throughout this report is moderate-to-severe active SLE in adults on background standard-of-care.
No actions were taken during the reporting interval by the sponsor, by any regulatory authority, by a Data and Safety Monitoring Board (DSMB), or by an ethics committee for safety or efficacy reasons that would meet the E2C(R2) reporting threshold. Specifically, during the interval there were:
The independent DSMB for OBX319-301 conducted its pre-specified periodic reviews of unblinded safety data throughout the treatment period and, at each review and at study completion, recommended continuation of the study without modification. The pattern and severity of adverse events remained consistent with the anticipated pharmacology of profound B-cell depletion and with the RSI; no unanticipated safety issue prompted a protocol amendment for safety reasons.
Because OBX-319 is not yet marketed, the RSI for this report is the Development Core Safety Information (DCSI) contained in the Safety Reference Information section of the current Investigator's Brochure. During the reporting interval the DCSI was revised to reflect the maturing programme understanding of the pharmacological consequences of dual CD19/CD20-directed B-cell depletion. The material RSI changes were:
The RSI does not contain, and no data in the interval warranted, any thyroid-related boxed warning or thyroid C-cell/medullary-thyroid-carcinoma precaution; such effects are not mechanistically plausible for a B-cell-depleting antibody and were not observed nonclinically or clinically. The complete tracked-change history of the DCSI is provided in Appendix 20.2.
Cumulative subject exposure derives entirely from the interventional clinical development programme. The pivotal Phase 3 study OBX319-301 was a randomized, double-blind, placebo-controlled trial that randomized 480 subjects in a 1:1:1 ratio to the two subcutaneous OBX-319 regimens (designated High and Low) or placebo on background standard-of-care over 52 weeks: 162 High, 158 Low, and 160 Placebo. Cumulative programme exposure, including the supportive earlier-phase studies, is summarised below.
| Study | Phase / design | OBX-319 subjects | Placebo/comparator | Total randomized |
|---|---|---|---|---|
| OBX319-101 | Phase 1, single/multiple ascending dose | 36 | 12 | 48 |
| OBX319-201 | Phase 2, dose-ranging | 88 | 44 | 132 |
| OBX319-301 | Phase 3, RDBPC, 1:1:1, 52 weeks (162 High / 158 Low / 160 Placebo) | 320 | 160 | 480 |
| Cumulative | 444 | 216 | 660 |
Cumulative exposure to OBX-319 across the programme is approximately 400 subject-years, the majority accrued in the 52-week pivotal study active arms. Exposure is characterised by subcutaneous administration only; there was no intravenous exposure in the marketed-route sense. Because the product is investigational, exposure is confined to the studied population — adults with moderate-to-severe active SLE (and, in Phase 1, the specified enrolment population) — with baseline disease activity in the pivotal trial reflected by a mean SLEDAI-2K of approximately 11. No paediatric, pregnancy, or lactation exposure occurred within the interventional programme, and there is no evidence of off-label or unapproved use because no product is on the market.
There is no post-marketing patient exposure to report. OBX-319 is not authorised and is not distributed commercially in any country; there is no compassionate-use, named-patient, or expanded-access exposure at the DLP. Consequently, no marketing exposure estimates (by indication, dose, region, age, or sex) can be presented, and Sections 6.3 and 8 contain no post-marketing data.
Adverse-event terms in this report and its appended tabulations were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version current at the DLP, and seriousness was assigned in accordance with ICH E2A/E2D criteria. Interval and cumulative counts are presented by System Organ Class and Preferred Term in the appended tabulations. No data-presentation convention changed during the interval that would affect comparability.
Cumulative summary tabulations of serious adverse events (SAEs) from the blinded and completed clinical trials are provided in Appendix 20.3. Consistent with the anticipated pharmacology of profound B-cell depletion, the SAE profile is dominated by the Infections and infestations System Organ Class, with a smaller contribution from administration-associated reactions. The tabulated SAE distribution is compatible with the RSI and with the class experience of B-cell-depleting therapy; no System Organ Class showed a cumulative pattern inconsistent with the recognised safety concerns of the molecule. These tabulations comprise SAEs irrespective of causality and are not, in isolation, a basis for causal inference; causal evaluation is presented in Sections 15 and 16.
Not applicable. There is no spontaneous, solicited, or non-interventional post-marketing data source for OBX-319 at the DLP.
OBX319-301 (Phase 3, randomized, double-blind, placebo-controlled, 1:1:1, 52 weeks, on background standard-of-care) completed during the interval and is the principal source of benefit and risk information in this report.
Efficacy. The primary endpoint was a composite responder endpoint — SRI-4 response with attainment of low disease activity (SLEDAI-2K ≤ 4) — at Week 52. In the primary efficacy analysis population, the endpoint was achieved by 52.4% (76/145) of High-dose subjects, 33.8% (49/145) of Low-dose subjects, and 6.0% (9/150) of placebo subjects, demonstrating a clear dose-related separation from placebo on both active regimens. The key secondary endpoint, the least-squares (LS) mean change from baseline in SLEDAI-2K at Week 52, was −6.37 for High-dose, −5.62 for Low-dose, and −3.46 for placebo, corresponding to placebo-adjusted LS-mean differences of −2.91 (High) and −2.17 (Low). The consistency of the responder and continuous SLEDAI-2K analyses, both favouring active treatment with a dose gradient, supports the robustness of the efficacy finding.
Pharmacodynamics and biomarkers. The pharmacodynamic effect was concordant with the intended mechanism: active treatment produced near-complete depletion of circulating CD19+ B cells, with mean counts falling from approximately 210 cells/µL at baseline to approximately 7 cells/µL, whereas CD19+ counts were essentially unchanged in the placebo arm. Depletion was accompanied by a decline in anti-double-stranded DNA (anti-dsDNA) antibodies and by normalisation of complement components C3 and C4 in responding subjects, providing serological corroboration that the clinical benefit is driven by removal of autoreactive B-cell populations and interruption of the downstream autoantibody/immune-complex pathway characteristic of SLE.
Safety. The interval safety experience from OBX319-301 was consistent with the RSI. Infections were the most frequently reported events and the principal driver of serious events; injection-site and systemic administration reactions and treatment-emergent ADA were observed as anticipated. Reductions in immunoglobulin concentrations consistent with hypogammaglobulinaemia were observed in a subset of actively treated subjects, in line with the expected consequence of sustained B-cell depletion. No new safety concern outside the recognised profile emerged, and the DSMB endorsed study completion.
An open-label long-term extension (OBX319-302) is ongoing for eligible completers of OBX319-301 to characterise durability of response, kinetics of B-cell repopulation, immunoglobulin trajectories, and long-term infection risk. No interim safety finding from the extension in this interval met the threshold for expedited action; accruing data remain consistent with the RSI.
Long-term follow-up is directed at the reversibility profile of the pharmacology: recovery of CD19+ B-cell counts after cessation of dosing, the time course and clinical significance of hypogammaglobulinaemia (including any need for immunoglobulin replacement), and delayed or opportunistic infection. Follow-up also monitors persistence and functional consequences (neutralising activity, PK impact) of ADA. No unexpected long-term signal was identified in the interval.
There was no other therapeutic use of OBX-319 during the interval. No compassionate-use, named-patient, expanded-access, or investigator-initiated use occurred.
Not applicable. OBX-319 is a single active substance and is not developed as a fixed-combination product. It is administered on background standard-of-care, but no fixed-dose combination is under development.
No non-interventional (observational) studies were completed or ongoing during the interval. A post-authorisation safety study (PASS) and a disease/exposure registry, including a pregnancy sub-registry, are planned as additional pharmacovigilance activities contingent on marketing authorization and are described in the Risk Management Plan; no findings are available at the DLP.
No sponsor-conducted clinical trials of OBX-319 other than those summarised in Section 7 were active in the interval, and there were no findings from other sponsor-held sources (e.g., pooled analyses, dedicated interaction or organ-impairment studies) that altered the safety understanding. Relevant external information on the therapeutic class — the safety experience of CD20-directed and CD19-directed B-cell-depleting agents in SLE and related autoimmune indications — is considered in the risk evaluation (Section 16) and the literature review (Section 11).
The nonclinical programme was designed and interpreted under ICH S6(R1) (preclinical safety evaluation of biotechnology-derived pharmaceuticals), consistent with the biology of a target-specific therapeutic antibody. Key features and interval status:
No new nonclinical finding in the interval altered the established hazard characterisation or the benefit-risk balance.
A systematic review of the scientific literature covering the interval was conducted. No published report described OBX-319 by name in a manner requiring RSI change. Class-relevant literature — encompassing the efficacy and safety of B-cell-depleting therapy in SLE and other autoimmune diseases, and the mechanistic rationale for combined CD19/CD20 targeting — was reviewed and reinforced the recognised risks that anchor the safety specification: serious and opportunistic infections, hypogammaglobulinaemia with prolonged depletion, rare PML as a class consideration, hepatitis B reactivation, blunted vaccine responses during depletion, and administration/immunogenicity reactions. Nothing in the literature identified a new signal or contradicted the established benefit-risk profile.
The content and data lock of this PBRER are aligned with the concurrent Development Safety Update Report (ICH E2F) for OBX-319 covering the same interval; the two documents are mutually consistent with respect to exposure, SAE tabulations, and the overall safety assessment. No divergent conclusions arise between periodic reports.
No information indicating a lack of efficacy that could constitute a safety signal arose during the interval. On the contrary, the completed controlled Phase 3 study OBX319-301 demonstrated statistically and clinically meaningful superiority of both active regimens over placebo on the primary composite responder endpoint (52.4% and 33.8% versus 6.0%) and on the key secondary continuous endpoint (SLEDAI-2K LS-mean change −6.37 and −5.62 versus −3.46), with concordant pharmacodynamic and serological effects. There is therefore no lack-of-efficacy concern for the proposed indication.
No late-breaking information became available after the DLP that would materially alter the benefit-risk evaluation presented in this report.
The signals evaluated during the interval, and their disposition, are summarised below. No signal was newly identified in the interval that fell outside the anticipated pharmacology of dual B-cell depletion; the recognised risks were confirmed and characterised rather than newly discovered.
| Signal | Status at DLP | Disposition |
|---|---|---|
| Serious infections | Ongoing (identified risk) | Confirmed; routine + additional pharmacovigilance; labelled |
| Opportunistic infections (incl. PML as class consideration) | Ongoing (potential risk) | Under continued surveillance; screening and monitoring measures |
| Hypogammaglobulinaemia | Closed → identified risk | Characterised; Ig monitoring and management guidance in RSI |
| Injection/administration reactions | Closed → identified risk | Characterised; monitoring guidance |
| Immunogenicity (ADA) with potential PK/PD impact | Ongoing (identified) | Monitored via ADA assays and exposure-response analyses |
| Hepatitis B reactivation | Ongoing (potential risk) | Pre-treatment screening; monitoring |
No signal required expedited regulatory action during the interval, and no signal was refuted and closed as a non-risk.
The safety specification deliberately does not include thyroid neoplasia or a thyroid boxed warning, which are not mechanistically relevant to a B-cell-depleting antibody.
Evaluation of the infection-related signals confirmed that risk is a direct, on-target consequence of profound B-cell depletion and the associated decline in immunoglobulins, consistent with the CD19+ depletion from approximately 210 to approximately 7 cells/µL observed on active treatment. The temporal association of infections with the period of maximal depletion, the biological plausibility, and the concordance with the established class experience support a causal relationship for serious infections and for hypogammaglobulinaemia. Administration reactions and ADA are expected pharmacological/immunological consequences of a subcutaneously delivered therapeutic antibody; evaluation showed the ADA response did not produce an unanticipated loss of pharmacodynamic effect at the population level, though ADA remains under active exposure-response surveillance.
The interval produced no new information that reclassified a potential risk to an identified risk beyond hypogammaglobulinaemia (already reflected in the RSI), and no new important risk was identified. The opportunistic-infection and PML considerations remain potential risks managed by screening, monitoring, and labelling. Hepatitis B reactivation is mitigated by mandatory pre-treatment screening. The overall risk profile at the DLP is unchanged in kind from the anticipated profile of a dual CD19/CD20-directed depleting antibody and is fully within the scope of the safety specification.
Because the product is not marketed, no post-authorisation effectiveness data for risk-minimisation measures exist. The proposed pharmacovigilance and risk-minimisation strategy (detailed in the Risk Management Plan) comprises routine measures (labelling, including infection and immunoglobulin-monitoring guidance, live-vaccine contraindication, and pre-treatment infectious-disease screening) and additional measures (healthcare-professional and patient educational materials, a patient safety card, a disease/exposure registry, a pregnancy sub-registry, and a PASS). Effectiveness will be assessed in subsequent PBRERs once post-authorisation experience accrues.
The pivotal evidence of benefit is study OBX319-301, a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe active SLE (baseline SLEDAI-2K approximately 11) on background standard-of-care. Both subcutaneous OBX-319 regimens produced clinically meaningful, dose-ordered improvement over placebo. The primary composite responder endpoint (SRI-4 with low disease activity, SLEDAI-2K ≤ 4) at Week 52 was achieved by 52.4% (76/145) High-dose, 33.8% (49/145) Low-dose, and 6.0% (9/150) placebo subjects. The key secondary endpoint, LS-mean change from baseline in SLEDAI-2K at Week 52, was −6.37 (High), −5.62 (Low), and −3.46 (placebo), giving placebo-adjusted differences of −2.91 and −2.17. These clinical effects were accompanied by the intended pharmacodynamic signature — near-complete CD19+ B-cell depletion (≈210 → ≈7 cells/µL) on active arms with unchanged counts on placebo — and by serological improvement (falling anti-dsDNA and normalising complement C3/C4 in responders), which together substantiate a mechanism-consistent, disease-modifying benefit.
No new efficacy information beyond the completed pivotal study became available in the interval that would alter the characterisation of benefit. The ongoing long-term extension (OBX319-302) is expected to inform durability and maintenance of response but did not yield interval conclusions affecting the benefit assessment.
The benefit of OBX-319 in moderate-to-severe active SLE is a clinically meaningful increase in the proportion of patients achieving low disease activity and a reduction in overall disease activity relative to placebo on background standard-of-care, supported by a coherent pharmacodynamic and serological response. The magnitude of the responder difference (46 percentage points for High-dose and 28 percentage points for Low-dose over placebo) is large in the context of SLE, where placebo-adjusted responses are typically modest, and the dose-ordered effect strengthens causal attribution. The benefit is relevant to a disease with high unmet need, substantial cumulative organ damage, and reliance on chronic glucocorticoids.
Moderate-to-severe active SLE is a chronic, relapsing autoimmune disease with meaningful morbidity and mortality and with organ damage accrual driven both by the disease and by long-term glucocorticoid and broad immunosuppressant exposure. Available therapies — glucocorticoids, antimalarials, mycophenolate and other conventional immunosuppressants, and the approved biologics belimumab and anifrolumab, together with off-label anti-CD20 B-cell depletion — leave a substantial proportion of patients with persistent activity, frequent flares, and steroid dependence. A therapy delivering deep, mechanism-based B-cell depletion with a durable clinical and serological response addresses a genuine unmet need, particularly for patients refractory to or intolerant of existing options.
The integrated assessment weighs a large, dose-ordered, mechanism-consistent clinical benefit (responder rates 52.4%/33.8% vs 6.0%; SLEDAI-2K LS-mean change −6.37/−5.62 vs −3.46, with serological normalisation) against a risk profile that is characteristic of, and largely predictable from, profound B-cell depletion — principally serious and opportunistic infections and hypogammaglobulinaemia, together with manageable administration reactions and monitored immunogenicity. The key risks are on-target, monitorable, and mitigable through pre-treatment screening, immunoglobulin and infection surveillance, vaccination before initiation, and defined management pathways. The subcutaneous route and the TMDD-informed dosing support a practical administration profile. The nonclinical programme, conducted appropriately in the cynomolgus monkey as the sole relevant species and correctly omitting genotoxicity, carcinogenicity, hERG, and thorough-QT evaluation, raised no hazard beyond the anticipated pharmacology. On balance, for adults with moderate-to-severe active SLE on background standard-of-care, the benefit of OBX-319 outweighs its risks when used with the specified risk-minimisation measures.
The benefit-risk balance of OBX-319 in the proposed indication of moderate-to-severe active SLE remains favourable at the DLP. No new safety signal emerged during the interval that lies outside the established safety specification, and the recognised risks — serious/opportunistic infections and hypogammaglobulinaemia foremost, with injection reactions and immunogenicity as expected accompaniments — are characterised and manageable. The efficacy demonstrated in OBX319-301, with mechanism-consistent pharmacodynamic and serological corroboration, supports a clinically meaningful benefit.
Planned and continuing actions:
No change to the development conduct or to the benefit-risk conclusion is required as a result of this reporting interval.